Prediction of risk for symptomatic sialadenitis by post-therapeutic dual 131I scintigraphy in patients with differentiated thyroid cancer
Authors:
- 7 August 2013
- journal article
- research article
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 27 (8) , 700-709
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Utility of Additional Delayed Post-Therapeutic 131I Whole-Body Scanning in Patients With Thyroid CancerClinical Nuclear Medicine, 2012
- The comparison of 131I whole-body scans on the third and tenth day after 131I therapy in patients with well-differentiated thyroid cancer: preliminary reportAnnals of Nuclear Medicine, 2011
- Improved Detection of Lung or Bone Metastases with an I-131 Whole Body Scan on the 7th Day After High-Dose I-131 Therapy in Patients with Thyroid CancerNuclear Medicine and Molecular Imaging, 2010
- Influence of Vitamin C on Salivary Absorbed Dose of 131I in Thyroid Cancer Patients: A Prospective, Randomized, Single-Blind, Controlled TrialJournal of Nuclear Medicine, 2010
- Radioactive Iodine and the Salivary GlandsThyroid®, 2003
- Scintigraphic Evaluation of Salivary Gland Dysfunction in Patients with Thyroid Cancer After Radioiodine TreatmentClinical Nuclear Medicine, 2002
- Quantification of salivary gland function in thyroid cancer patients treated with radioiodineInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1996
- Differential kinetics of parotid and submandibular gland function as demonstrated by scintigraphic means and its possible implicationsNuclear Medicine Communications, 1995
- 99mTc-pertechnetate uptake in parotid acinar cells by the Na+/K+/Cl- co-transport system.Journal of Clinical Investigation, 1987
- Iodine 131 total body scan—extrathyroidal uptake of radioiodineSeminars in Nuclear Medicine, 1986